𝐐: 𝐖𝐞 𝐮𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝 𝐭𝐡𝐚𝐭 𝐲𝐨𝐮 𝐡𝐚𝐯𝐞 𝐛𝐞𝐞𝐧 𝐢𝐧𝐯𝐨𝐥𝐯𝐞𝐝 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 𝐃𝐓𝐑𝐈𝐏4𝐇 𝐩𝐫𝐨𝐣𝐞𝐜𝐭 𝐬𝐢𝐧𝐜𝐞 𝐢𝐭𝐬 𝐢𝐝𝐞𝐚 𝐬𝐭𝐚𝐠𝐞. 𝐂𝐨𝐮𝐥𝐝 𝐲𝐨𝐮 𝐬𝐡𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐮𝐬 𝐰𝐡𝐚𝐭 𝐢𝐧𝐬𝐩𝐢𝐫𝐞𝐝 𝐭𝐡𝐞 𝐃𝐓𝐑𝐈𝐏4𝐇 𝐩𝐫𝐨𝐣𝐞𝐜𝐭 𝐚𝐧𝐝 𝐭𝐡𝐢𝐬 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧?
A: We are 23 partners in this project, and the inspiration came from one of our colleagues who introduced the concept of data harmonization. Right now, within the digital health industry, we have technology installed, but everyone has their own way of working. The data is not harmonized from one point to another, and there's no interface. This is one of the major gaps we’ve identified, and it's exactly what we aim to address through this project.

𝐐: 𝐂𝐨𝐮𝐥𝐝 𝐲𝐨𝐮 𝐞𝐱𝐩𝐥𝐚𝐢𝐧 𝐢𝐧 𝐬𝐢𝐦𝐩𝐥𝐞 𝐭𝐞𝐫𝐦𝐬 𝐰𝐡𝐚𝐭 𝐢𝐬 𝐛𝐞𝐡𝐢𝐧𝐝 𝐭𝐡𝐞 𝐃𝐓𝐑𝐈𝐏4𝐇 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧? 𝐀𝐧𝐝 𝐡𝐨𝐰 𝐰𝐢𝐥𝐥 𝐢𝐭 𝐚𝐟𝐟𝐞𝐜𝐭 𝐭𝐡𝐞 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐡𝐞𝐚𝐥𝐭𝐡 𝐬𝐞𝐜𝐭𝐨𝐫?
A: The main innovation is the creation of a decentralized digital twin and data harmonization, so that there is an interface - allowing data from the hardware to the software side, from medical clinics - to communicate with each other and provide the right solution to the end user.

It will affect the European health sector in a significant way. As we know, in Europe, every country has its own language, its own data format, and its own regulations. When we travel from one country to another - or when a doctor needs input from a specialist in another country - it's very difficult to harmonize things. What one doctor enters into the system may not be understood by another, because the system itself cannot interpret the differences. DTRIP4H creates a platform to overcome this challenge, so that any patient from any part of Europe can be properly treated by a doctor in any other part.

𝐐: 𝐂𝐨𝐮𝐥𝐝 𝐲𝐨𝐮 𝐭𝐞𝐥𝐥 𝐮𝐬 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐮𝐬𝐞 𝐜𝐚𝐬𝐞𝐬 𝐰𝐡𝐞𝐫𝐞 𝐭𝐡𝐢𝐬 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐭𝐞𝐬𝐭𝐞𝐝?
A: We have seven use cases in this project, I’d like to mention. Use case one is about medical imaging and environment-based digital twins. Use case two focuses on a virtual reality drug combiner. Use case three involves the assessment of inhalation exposure in urban areas. Use case four — which is also personally very interesting to me — is about testing cancer medicine without the need to use animals, by creating a digital twin and testing the medicine within that environment. Use case five relates to precision treatment development for schizophrenia. So, these are the five predefined use cases, but two additional use cases in the healthcare sector will be developed during the project.

𝐐: 𝐖𝐡𝐚𝐭 𝐝𝐨 𝐲𝐨𝐮 𝐬𝐞𝐞 𝐚𝐬 𝐭𝐡𝐞 𝐦𝐚𝐢𝐧 𝐠𝐨𝐚𝐥 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐜𝐨𝐧𝐬𝐨𝐫𝐭𝐢𝐮𝐦 𝐭𝐞𝐚𝐦 𝐚𝐭 𝐭𝐡𝐞 𝐛𝐞𝐠𝐢𝐧𝐧𝐢𝐧𝐠 𝐨𝐟 𝐭𝐡𝐞 𝐩𝐫𝐨𝐣𝐞𝐜𝐭?
A: The first year of the project is very crucial because we all come from different parts of Europe. So, synchronizing ourselves and aligning on what we are doing is essential — especially since many partners will be working together as a team for the first time. Team development is therefore very important for us.
It’s also critical for the technical development team to understand the different data formats, because data needs to be collected in order to proceed with further application development. From the ethical point of view, it’s also about aligning everything in a responsible way, since AI development is involved. So, we need to establish our AI ethics framework.

Overall, the first year is about synchronizing the whole team, so that from the second year onward, we can fully focus on development work.

𝘔𝘢𝘯𝘺 𝘵𝘩𝘢𝘯𝘬𝘴 𝘧𝘰𝘳 𝘺𝘰𝘶𝘳 𝘷𝘢𝘭𝘶𝘢𝘣𝘭𝘦 𝘪𝘯𝘴𝘪𝘨𝘩𝘵𝘴, 𝘔𝘳. 𝘙𝘢𝘩𝘶𝘭 𝘛𝘰𝘮𝘢𝘳. 𝘉𝘦𝘴𝘵 𝘰𝘧 𝘭𝘶𝘤𝘬 𝘢𝘴 𝘺𝘰𝘶 𝘮𝘰𝘷𝘦 𝘧𝘰𝘳𝘸𝘢𝘳𝘥 𝘸𝘪𝘵𝘩 𝘵𝘩𝘪𝘴 𝘱𝘳𝘰𝘫𝘦𝘤𝘵 𝘢𝘯𝘥 𝘵𝘦𝘢𝘮!